Company intelligence / Profile preview

SCOHIA PHARMA, Inc.

Fujisawa, Kanagawa, Japanscohia.com ↗

Ownership: Private
Employees: ~7
Development stage: Phase 1

Overview

The company has multiple programs in development, with its lead candidate Imarikiren hydrochloride (renin inhibitor) in Phase 2 for diabetic nephropathy. SCO-240 (SSTR5 antagonist) and SCO-267 (GPR40 agonist) are in Phase 1 trials for infertility/growth hormone disorders and obesity, respectively. Several preclinical programs are also in development.

Therapeutic areas: Women's HealthEndocrinologyCardiovascularNephrology
Modalities: Small molecule drugsSynthetic peptides
Industry: Biotech

Drug pipeline

9 assets

imarikiren

8 more assets in the full pipeline.

Request access →

Partnerships

Takeda Pharmaceutical Company LimitedMEDIPAL Holdings Corporation

Beyond the preview

Go deeper on SCOHIA PHARMA, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCOHIA PHARMA, Inc..

Explore the full profile